<DOC>
	<DOCNO>NCT00321620</DOCNO>
	<brief_summary>The purpose study determine denosumab non-inferior zoledronic acid ( ZometaÂ® ) treatment bone metastases men hormone-refractory prostate cancer</brief_summary>
	<brief_title>Study Denosumab vs. Zoledronic Acid Treat Bone Metastases Men With Hormone-refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Bone Marrow Diseases</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Men &gt; /= 18 year age histologically confirm prostate cancer Radiographic evidence least one bone metastasis Failure least one hormonal therapy evidence rise PSA Serum testosterone level &lt; 50 ng/dL ECOG PS 0 , 1 , 2 Adequate organ function Current prior IV bisphosphonate administration Current prior oral bisphosphonates bone mets Life expectancy le 6 month</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Bone metastasis</keyword>
	<keyword>Hormone-refractory prostate cancer</keyword>
	<keyword>Skeletal</keyword>
	<keyword>Fractures</keyword>
	<keyword>Compressions</keyword>
	<keyword>Bisphosphonates</keyword>
</DOC>